Abstract
Acetazolamide is commonly used as an empirical treatment for inherited periodic paralyses although some patients may develop deleterious effects. We report a 65. year-old man with hyperkalemic periodic paralysis and late-onset permanent weakness in association with the common T704M mutation in α-subunit, skeletal muscle voltage-gated sodium channel gene. He rapidly recovered from weakness after acetazolamide treatment. Magnetic resonance imaging of thighs comparing pre- and post-treatment revealed a significant increase in muscle bulk. The patient has been without any type of weakness for over 6. years. This data show the remarkable benefit of acetazolamide on permanent weakness of hyperkalemic periodic paralysis in association with the T704M mutation.
| Original language | English |
|---|---|
| Pages (from-to) | 445-449 |
| Number of pages | 5 |
| Journal | Neuromuscular Disorders |
| Volume | 23 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2013 |
Keywords
- Acetazolamide
- Hyperkalemic periodic paralysis
- Muscle channelopathies
- SCN4A gene
- T704M mutation
Fingerprint
Dive into the research topics of 'Long-term effectiveness of acetazolamide on permanent weakness in hyperkalemic periodic paralysis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver